Posts found in:
Grantees

Project Title: New principles for designing chimeric antigen receptors Project description: CAR-T cells represent a revolutionary tool for targeted treatment of leukemias and lymphomas. However, the mechanisms by which these cells attack tumor remains unclear. Our project aims to clarify and leverage the biophysical properties of CAR-T cell signaling to improve treatment of blood cancers.

Title of Grant:       Engineered Natural Killer Cell Therapies Targeting Acute Myeloid Leukemia Description: Acute myeloid leukemia (AML) is a highly prevalent form of blood cancer with extremely low survival rates. Therapies that activate the patient’s immune system to fight disease have been successful in many leukemias, but not AML. We will create a new immune-activating […]

Title of Grant: Dietary Serine Modulation as a Precision Nutrition Therapy for AML Description: Integrative cancer treatments incorporating diet are needed. We have found that certain patients with acute myeloid leukemia may benefit from a dietary intervention affecting the amino acid serine. We propose studies to better understanding and improve upon this intervention so that […]

Fox Chase Cancer Center Title of Grant: Investigating the essential roles of Kelch-like family member KLHL11 in the pathogenesis of Anaplastic Large Cell Lymphoma and in normal T cells Description:          This project will seek to address the importance of a novel E3 ligase, KLHL11, in the pathogenesis of T cell lymphoma and in normal T […]

Title of Grant:       Role of co-stimulatory domains in CAR T cell dysfunction Description: Cell-based immune therapies have demonstrated impressive success in the treatment of blood cancers, however most patients treated with available cellular immunotherapies are not cured. The goal of this proposal is to identify the molecular pathways responsible for failure of these therapies and […]

Title of Grant:       Dissecting the role of the unfolded protein response in type 1 CALRmutated myelofibrosis  Description: The experiments proposed will help to answer why, among the two types of CALR mutations found in MPN patients, only one type causes myelofibrosis, the most deadly and difficult to treat disease among the three MPN types. This […]

Title of Grant:       Elucidating and targeting IDH2 mutations in T cell lymphoma  Description: Drugs that target mutant forms of the metabolic enzyme isocitrate dehydrogenase 2 (IDH2) are a promising appraoch to treat some cancers. The proposed research will uncover how mutant IDH2 causes T cell lymphoma and determine whether inhibiting mutant IDH2 offers an effective […]

Title of Grant: “Development of anti-KIT antibodies and immunotoxins as therapeutics and HSCT conditioning agents for pediatric acute myeloid leukemia (AML)” Acute myeloid leukemia (AML) is a frequent type of leukemia with harsh treatments and poor outcomes. We have pioneered several new antibody therapies targeting an important receptor found both on blood stem cells and AML, […]

“Increasing the Therapeutic Index of Chimeric Antigen Receptor T cells for T cell Lymphomas” Our goal is to bring the unquestioned power of CAR T cell therapy to bear on T cell lymphomas, a group of diseases with a poor prognosis and few treatment options. We will use the latest gene-editing tools to make an […]

“Reconstructing the differentiation dynamics and genealogy of cancer cells in individual patients with myeloproliferative neoplasms using single-cell sequencing” In a type of blood cancer called myeloproliferative neoplasm, the same genetic alteration results in drastically different forms of the disease in different patients. To understand this discrepancy, we will measure the molecular profile of individual cells […]

“Targeting the Innate Immunity-Independent Function of STING in treating AML” This proposal is to test if inhibiting a deubiquitinase named OTUD7B retards AML growth. We found that AML growth is controlled by an immunity sensor STING through activating an oncogenic kinase called mTOR. This process is facilitated by OTUD7B. Thus, inhibiting OTUD7B suppresses STING-mediated mTOR […]

“A simple dietary supplement to improve pediatric blood cancer therapy” We propose to improve the use of methotrexate – the standard pediatric leukemia drug – with a simple dietary supplement. By enhancing methotrexate’s efficacy, and better monitoring patients’ responses to the drug, we aim to reduce the therapy’s long-term side effects and offer hope to […]